β-amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: Relevance to Alzheimer's disease

Journal of Neurochemistry

Volumn 72, Issue 1, 1999, Pages 230-237

  Pillot, Thierry ^a,d   Goethals, Marc ^b   Najib, Jamilla ^e   Labeur, Christine ^a   Lins, Laurence ^c   Chambaz, Jean ^d   Brasseur, Robert ^c   Vandekerckhove, Joel ^b   Rosseneu, Maryvonne ^a  

^a GHENT UNIVERSITY   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e UNIV LILLE   (France)

Author keywords

Amyloid peptide; Alzheimer's disease; Apolipoprotein E; Peptide peptide interaction

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E;

ALZHEIMER DISEASE; ARTICLE; CIRCULAR DICHROISM; DEMENTIA; HUMAN; PEPTIDE SYNTHESIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; RECEPTOR BINDING;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEINS E; BINDING SITES; HUMANS; LIPID METABOLISM; LIPOSOMES; MEMBRANE FUSION; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY;

EID: 0032951957     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1999.0720230.x     Document Type: Article

References (40)

1. Aggerbeck L. P., Wetterau J. R., Weisgraber K. H., Wu C.-S. C., and Lindgren F. T. (1988) Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyterminal domains. J. Biol. Chem. 263, 6249-6258.
2. Aizawa Y., Fukatsu R., Takamaru Y., Tsuzuki K., Chiba H., Kobayashi K., Fujii N., and Takahata N. (1997) Amino-terminus truncated apolipoprotein E is the major species in amyloid deposits in Alzheimer's disease-affected brains: a possible role for apolipoprotein E in Alzheimer's disease. Brain Res. 768, 208-214.
3. Aleshkov S., Abraham C. R., and Zannis V. I. (1997) Interaction of nascent apoE2, apoE3, and apoE4 isoforms expressed in mammalian cells with amyloid peptide β (1-40). Relevance to Alzheimer's disease. Biochemistry 36, 10571-10580.
4. Brasseur R., Vanloo B., Deleys R., Lins L., Labeur C., Taveirne J., Ruysschaert J. M., and Rosseneu M. (1993) Synthetic model peptides for apolipoproteins. I. Design and properties of synthetic model peptides for the amphipathic helices of plasma apolipoproteins. Biochim. Biophys. Acta 1170, 1-7.
5. Brasseur R., Pillot T., Lins L., Vandekerckhove J., and Rosseneu M. (1997) Peptides in membranes: tipping the balance of membrane stability. Trends Biochem. Sci. 22, 167-171.
6. Castano E. M., Prelli F., Wisniewski T., Golabek A., Kumar R. A., Soto C., and Frangione B. (1995a) Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem. J. 306, 599-604.
7. Castano E. M., Prelli F., Pras M., and Frangione B. (1995b) Apolipoprotein E carboxyl-terminal fragments are complexed to amyloids A and L. Implication for amyloidogenesis and Alzheimer's disease. J. Biol. Chem. 270, 17610-17615.
8. Corder E. H., Saunders A, M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L., and Pericak-Vance M. A. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late-onset families. Science 261, 921-923.
9. De Pauw M., Vanloo B., Weisgraber K. H., and Rosseneu M. (1995) Comparison of lipid-binding and lecithin:cholesterol acyltransferase activation of the amino- and carboxy-terminal domains of human apolipoprotein E3. Biochemistry 34, 10953-10960.
10. Dong L. M. and Weisgraber K. H. (1996) Human apolipoprotein E4 domain interaction: arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J. Biol. Chem. 271, 19053-19057.
11. Dong L. M., Wilson C., Wardell M. R., Simmons T., Mahley R. W., Weisgraber K. H., and Agard D. A. (1994) Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J. Biol. Chem. 269, 22358-22365.
12. Golabek A., Soto C., Vogel T., and Wisniewski T. (1996) The interaction between apolipoprotein E and Alzheimer's amyloid β-peptide is dependent on β-peptide conformation. J. Biol. Chem. 271, 10602-10606.
13. Innerarity T. L., Friedlander E. J., Rall S. C. Jr., Weisgraber K. H., and Mahley R. W. (1983) The receptor binding domain of human apolipoprotein E3. Binding of apolipoprotein E fragments. J. Biol. Chem. 258, 12341-12347.
14. LaDu M. J., Falduto M. T., Manelli A. M., Reardon C. A., Getz G. S., and Frail D. E. (1994) Isoform-specific binding of apolipoprotein E to beta-amyloid. J. Biol. Chem. 269, 23403-23406.
15. LaDu M. J., Lukens J. R., Reardon C. A., and Getz G. S. (1997) Association of human, rat, and rabbit apolipoprotein E with β-amyloid. J. Neurosci. Res. 49, 9-18.
16. Laemmli U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
17. Lalowski M., Golabek A. A., Lemere C. A., Selkoe D. J., Wisniewski H. M., Beavis R. C., Frangione B., and Wisniewski T. (1996) The non-amyloidogenic p3 fragment (Aβ17-42) is a major constituent of Down syndrome cerebellar preamyloid. J. Biol. Chem. 271, 33623-33631.
18. Lansbury P. T., Costa P. R., Griffiths J. M., Simon E. J., Auger M., Halverson K. J., Kocisko D. A., Hendsch Z. S., Ashburn T. T., Spencer R. G. S., Tidor B., and Griffin R. G. (1995) Structural model for the β-amyloid fibril based on interstrand alignment of an anti-parallel-sheet comprising a C-terminal peptide. Nat. Struct. Biol. 2, 990-998.
19. Mahley R. W., Innerarity T. L., Rall S. C., Weisgraber K. H., and Taylor J. M. (1990) Apolipoprotein E: genetic variants provide insights into its structure and function. Curr. Opin. Lipidol. 1, 87-95.
20. Namba Y., Tomonaga M., Kawasaki H., Otomo E., and Ikeda K. (1991) Apolipoprotein E immunoreactivity in cerebral deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541, 163-166.
21. Naslund J., Thyberg J., Tjenberg L. O., Wernstedt C., Karlstrom A. R., Bogdanovic N., Gandy S. E., Lannfelt L., Terenius L., and Nordstedt C. (1995) Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain. Neuron 15, 219-228.
22. Nolte R. T. and Atkinson D. (1992) Conformational analysis of apolipoprotein A-I and E-3 based on primary sequence and circular dichroism. Biophys. J. 63, 1221-1239.
23. Pillot T., Goethals M., Vanloo B., Talussot C., Brasseur R., Rosseneu M., Vandekerckhove J., and Lins L. (1996a) Fusogenic properties of the C-terminal domain of the Alzheimer β-amyloid peptide. J. Biol. Chem. 271, 28757-28765.
24. Pillot T., Barbier A., Visvikis A., Lozac'h K., Rosseneu M., Vandekerckhove J., and Siest G. ( 1996b) Single step purification of two functional apolipoprotein E variants hyperexpressed in E. coli. Prot. Express. Purif. 7, 407-414.
25. Pillot T., Goethals M., Vanloo B., Lins L., Brasseur R., Vandekerckhove J., and Rosseneu M. (1997a) Specific modulation of the fusogenic properties of the Alzheimer β-amyloid peptide by apolipoprotein E isoforms. Eur. J. Biochem. 243, 650-659.
26. Pillot T., Lins L., Goethals M., Vanloo B., Baert J., Vandekerckhove J., Rosseneu M., and Brasseur R. (1997b) The 118-135 peptide of the human prion protein forms amyloid fibrils and induces liposome fusion. J. Mol. Biol 274, 381-393.
27. Rosseneu M. and Labeur C. (1995) Physiological significance of apolipoprotein mutants. FASEB J. 9, 768-776.
28. Sparrow J. T., Sparrow D. A., Fernando G., Culwell A. R., Kovar M., and Gotto A. M. Jr. (1992) Apolipoprotein E: phospholipid binding studies with synthetic peptides from the carboxyl terminus. Biochemistry 31, 1065-1068.
29. Strittmatter W. J., Saunders A., Schmechel D., Pericak-Vance M., Englhild J., Salvesen O. S., and Roses A. D. (1993a) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 1977-1981.
30. Strittmatter W. J., Weisgraber K. H., Huang D. Y., Dong L. M., Salvesen G. S., Pericak-Vance M., Schmechel D., Saunders A. M., Goldgaber D., and Roses A. D. (19936) Binding of human apolipoprotein E to synthetic amyloid beta-peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 8098-8102.
31. 1H NMR. Biochemistry 35, 10358-10366.
32. Weisgraber K. H. (1990) Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112. J. Lipid Res. 31, 1503-1511.
33. Weisgraber K. H. (1994) Apolipoprotein E: structure-function relationship, in Advances in Protein Chemistry, Vol. 45 (Schumaker V. N., ed), pp. 249-295. Academic Press, San Diego.
34. Weisgraber K. H. and Mahley R. W. (1996) Human apolipoprotein E: the Alzheimer's disease connection. FASEB J. 10, 1485-1494.
35. Wetterau J. R., Aggerbeck L. P., Rall S. C. Jr., and Weisgraber K. H. (1988) Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J. Biol. Chem. 263, 6240-6248.
36. Wilson C., Wardell M. R., Weisgraber K. H., Mahley R. W., and Agard D. A. (1991) Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 252, 1817-1822.
37. Wisniewski T. and Frangione B. (1992) Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett. 135, 235-238.
38. Wisniewski T., Golabek A., Kida E., Wisniewski K. E., and Frangione B. (1995) Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis. Am. J. Pathol. 147, 238-244.
39. Yang D. S., Smith J. D., Zhou Z., Gandy S. E., and Martins R. N. (1997) Characterization of the binding of amyloid-β peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. J. Neurochem. 68, 721-725.
40. Zhou Z., Smith J. D., Greengard P., and Gandy S. (1996) Alzheimer amyloid-β peptide forms denaturant-resistant complex with type E3 but not type E4 isoform of native apolipoprotein E. Mol. Med. 2, 175-180.